Antibiotics in the clinical pipeline in 2013

被引：311

作者：

Butler, Mark S. ^{[1
]}

Blaskovich, Mark A. ^{[1
]}

Cooper, Matthew A. ^{[1
]}

机构：

[1] Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld 4072, Australia

来源：

JOURNAL OF ANTIBIOTICS | 2013年 / 66卷 / 10期

基金：

澳大利亚国家健康与医学研究理事会; 英国惠康基金;

关键词：

antimicrobial resistance; antibiotic; clinical trials; drug development; drug discovery; natural product; IN-VITRO ACTIVITY; SKIN-STRUCTURE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; PEPTIDE DEFORMYLASE INHIBITOR; BETA-LACTAMASE INHIBITOR; RESEARCH-AND-DEVELOPMENT; GRAM-NEGATIVE BACTERIA; CLOSTRIDIUM-DIFFICILE INFECTION; MYCOBACTERIAL ATP SYNTHASE; FATTY-ACID BIOSYNTHESIS;

D O I：

10.1038/ja.2013.86

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

The continued emergence of multi-drug-resistant bacteria is a major public health concern. The identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections. This review lists the 22 new antibiotics launched since 2000 and details the two first-in-class antibiotics, fidaxomicin (1) and bedaquiline (2), launched in 2011 and 2012, respectively. The development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of the 49 compounds and 6 beta-lactamase/beta-lactam combinations in active clinical development are discussed, as well as compounds that have been discontinued from clinical development since 2011. New antibacterial pharmacophore templates are also reviewed and analyzed.

引用

页码：571 / 591

页数：21

共 255 条

[1]

Synthesis and Spectrum of the Neoglycoside ACHN-490 [J].

Aggen, James B. ;

Armstrong, Eliana S. ;

Goldblum, Adam A. ;

Dozzo, Paola ;

Linsell, Martin S. ;

Gliedt, Micah J. ;

Hildebrandt, Darin J. ;

Feeney, Lee Ann ;

Kubo, Aya ;

Matias, Rowena D. ;

Lopez, Sara ;

Gomez, Marcela ;

Wlasichuk, Kenneth B. ;

Diokno, Raymond ;

Miller, George H. ;

Moser, Heinz E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) :4636-4642

[2]

Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes [J].

Al-Lahham, A ;

De Souza, NJ ;

Patel, M ;

Reinert, RR .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (06) :1130-1133

[3]

Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480 [J].

Alffenaar, J. W. C. ;

van der Laan, T. ;

Simons, S. ;

van der Werf, T. S. ;

van de Kasteele, P. J. ;

de Neeling, H. ;

van Soolingen, D. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) :1287-1289

[4]

Evolution of antibiotic resistance at non-lethal drug concentrations [J].

Andersson, Dan I. ;

Hughes, Diarmaid .

DRUG RESISTANCE UPDATES, 2012, 15 (03) :162-172

[5]

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[6]

[Anonymous], 2012, Nat Rev Microbiol, V10, P373

[7]

[Anonymous], 2010, US Pat, Patent No. [US2010184649, 2010184649, 2010/184649]

[8]

[Anonymous], 2012, US Pat, Patent No. [8 318 706, 8318706, 8,318,706]

[9]

[Anonymous], GUID IND ANT THER PA

[10]

[Anonymous], 2009, UN COLL TB ALL TIB A

← 1 2 3 4 5 6 7 8 9 10 →